Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs
This article was originally published in PharmAsia News
Executive Summary
The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.
You may also be interested in...
Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market